Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IINN NASDAQ:PDEX NASDAQ:SMTI NASDAQ:TLSI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIINNInspira Technologies OXY B.H.N.$1.52+109.1%$0.50$0.34▼$1.65$54.64M2.16352,435 shs213.21 million shsPDEXPro-Dex$64.58-0.9%$53.72$23.47▼$66.75$208.01M-0.1231,865 shs31,885 shsSMTISanara MedTech$23.38+2.0%$19.33$16.05▼$35.95$210.13M1.1647,300 shs23,168 shsTLSITriSalus Life Sciences$3.19-0.9%$4.00$2.20▼$7.95$197.76M0.56729,705 shs278,358 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIINNInspira Technologies OXY B.H.N.+109.08%+290.75%+198.62%+157.98%+244.28%PDEXPro-Dex-0.87%+1.75%+24.29%+44.54%+46.41%SMTISanara MedTech+1.96%+1.65%+23.51%+10.96%-24.04%TLSITriSalus Life Sciences-0.93%-1.54%-29.11%-40.71%-42.93%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIINNInspira Technologies OXY B.H.N.$1.52+109.1%$0.50$0.34▼$1.65$54.64M2.16352,435 shs213.21 million shsPDEXPro-Dex$64.58-0.9%$53.72$23.47▼$66.75$208.01M-0.1231,865 shs31,885 shsSMTISanara MedTech$23.38+2.0%$19.33$16.05▼$35.95$210.13M1.1647,300 shs23,168 shsTLSITriSalus Life Sciences$3.19-0.9%$4.00$2.20▼$7.95$197.76M0.56729,705 shs278,358 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIINNInspira Technologies OXY B.H.N.+109.08%+290.75%+198.62%+157.98%+244.28%PDEXPro-Dex-0.87%+1.75%+24.29%+44.54%+46.41%SMTISanara MedTech+1.96%+1.65%+23.51%+10.96%-24.04%TLSITriSalus Life Sciences-0.93%-1.54%-29.11%-40.71%-42.93%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIINNInspira Technologies OXY B.H.N. 2.00Hold$2.0031.58% UpsidePDEXPro-Dex 2.33Hold$70.008.39% UpsideSMTISanara MedTech 2.00Hold$34.0045.42% UpsideTLSITriSalus Life Sciences 2.25Hold$7.50135.11% UpsideCurrent Analyst Ratings BreakdownLatest IINN, SMTI, PDEX, and TLSI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2026PDEXPro-Dex Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/13/2026TLSITriSalus Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/13/2026TLSITriSalus Life Sciences Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $8.005/12/2026PDEXPro-Dex Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$56.00 ➝ $70.005/12/2026SMTISanara MedTech Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/1/2026PDEXPro-Dex Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)4/21/2026SMTISanara MedTech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/15/2026SMTISanara MedTech Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$32.004/10/2026IINNInspira Technologies OXY B.H.N. Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/10/2026TLSITriSalus Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/6/2026TLSITriSalus Life Sciences Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $7.00(Data available from 5/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIINNInspira Technologies OXY B.H.N.$289K189.07N/AN/A$0.06 per share25.33PDEXPro-Dex$66.59M3.09$3.11 per share20.78$14.16 per share4.56SMTISanara MedTech$103.12M2.08$0.61 per share38.57$0.77 per share30.36TLSITriSalus Life Sciences$45.15M4.34N/AN/A$0.21 per share15.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIINNInspira Technologies OXY B.H.N.-$13.22MN/AN/AN/AN/AN/AN/AN/A8/6/2026 (Estimated)PDEXPro-Dex$8.98M$3.6217.8423.23N/A16.08%22.78%14.30%7/8/2026 (Estimated)SMTISanara MedTech-$37.56M-$3.77N/AN/AN/A-31.23%-3.19%-0.56%8/12/2026 (Estimated)TLSITriSalus Life Sciences-$39.23M-$1.41N/AN/AN/A-60.85%N/A-69.91%8/11/2026 (Estimated)Latest IINN, SMTI, PDEX, and TLSI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/30/2026Q3 2026PDEXPro-Dex$0.62$1.20+$0.58$1.20$17.90 million$19.95 million3/24/2026Q4 2025SMTISanara MedTech$0.11$0.04-$0.07-$0.19$27.90 million$27.55 million3/5/2026Q4 2025TLSITriSalus Life Sciences-$0.13-$0.12+$0.01-$0.21$13.20 million$13.21 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthIINNInspira Technologies OXY B.H.N.N/AN/AN/AN/AN/APDEXPro-DexN/AN/AN/AN/AN/ASMTISanara MedTechN/AN/AN/AN/AN/ATLSITriSalus Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIINNInspira Technologies OXY B.H.N.0.081.561.30PDEXPro-Dex0.323.672.14SMTISanara MedTech6.592.282.05TLSITriSalus Life Sciences2.585.785.46Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIINNInspira Technologies OXY B.H.N.12.72%PDEXPro-Dex15.28%SMTISanara MedTech8.10%TLSITriSalus Life Sciences2.58%Insider OwnershipCompanyInsider OwnershipIINNInspira Technologies OXY B.H.N.29.40%PDEXPro-Dex45.90%SMTISanara MedTech42.00%TLSITriSalus Life Sciences16.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIINNInspira Technologies OXY B.H.N.2035.95 million25.38 millionNot OptionablePDEXPro-Dex1403.19 million1.73 millionNot OptionableSMTISanara MedTech609.16 million5.32 millionNot OptionableTLSITriSalus Life Sciences10661.42 million51.41 millionNot OptionableIINN, SMTI, PDEX, and TLSI HeadlinesRecent News About These CompaniesTLSI ALERT: Levi & Korsinsky Investigates TriSalus Life Sciences, Inc. on Behalf of Shareholders Who Lost MoneyMay 24, 2026 | newsfilecorp.comNTLSI (TLSI) Securities Fraud Investigation - Levi & KorsinskyMay 22, 2026 | prnewswire.comSecurities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced - Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading ...May 20, 2026 | tmcnet.comSecurities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law FirmMay 20, 2026 | businesswire.comTriSalus Life Sciences Inc. (TLSI) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud InvestigationMay 20, 2026 | businesswire.comSecurities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced - Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. CruzMay 19, 2026 | tmcnet.comLost Money on TriSalus Life Sciences, Inc. (TLSI)? Possible Fraud - Contact Levi & Korsinsky TodayMay 19, 2026 | newsfilecorp.comNTLSI Investor Alert: Levi & Korsinsky Investigates TLSI (TLSI) for Potential Securities FraudMay 19, 2026 | businesswire.comSecurities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. CruzMay 19, 2026 | businesswire.comTriSalus Life Sciences (NASDAQ:TLSI) Director Purchases $24,600.00 in StockMay 19, 2026 | insidertrades.comLost Money on TriSalus Life Sciences, Inc. (TLSI)? Contact Levi & Korsinsky to Protect Your RightsMay 14, 2026 | newsfilecorp.comNTriSalus outlines $54M-$57M 2026 revenue forecast while TriNav Advance clearance runs ~5 months past goalMay 14, 2026 | seekingalpha.comTriSalus Life Sciences Q1 Earnings Call HighlightsMay 12, 2026 | marketbeat.comTriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue EstimatesMay 12, 2026 | zacks.comEarnings To Watch: TriSalus Life Sciences Inc (TLSI) Reports Q1 2026 ResultMay 11, 2026 | finance.yahoo.comTriSalus (TLSI) Initiates Patient Enrollment for PREDICTT Liver Tumor Clinical TrialMay 10, 2026 | uk.finance.yahoo.comLake Street Remains a Buy on TriSalus Life Sciences (TLSI)May 7, 2026 | theglobeandmail.comTriSalus Life Sciences (TLSI) Projected to Post Quarterly Earnings on TuesdayMay 5, 2026 | marketbeat.comTriSalus Life Sciences Announces Launch of PREDICTT Clinical Trial Evaluating Pressure-Enabled Drug Delivery in Liver TumorsMay 4, 2026 | businesswire.comTriSalus Life Sciences Announces Planned Clinical Leadership TransitionApril 29, 2026 | tipranks.comTriSalus Life Sciences to Host First Quarter 2026 Financial Results Conference CallApril 28, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIINN, SMTI, PDEX, and TLSI Company DescriptionsInspira Technologies OXY B.H.N. NASDAQ:IINN$1.52 +0.79 (+109.08%) As of 05/26/2026Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. Inspira Technologies Oxy B.H.N. Ltd. was incorporated in 2018 and is headquartered in Ra'annana, Israel.Pro-Dex NASDAQ:PDEX$64.58 -0.57 (-0.87%) Closing price 05/27/2026 04:00 PM EasternExtended Trading$63.74 -0.84 (-1.29%) As of 05/27/2026 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.Sanara MedTech NASDAQ:SMTI$23.38 +0.45 (+1.96%) Closing price 05/27/2026 04:00 PM EasternExtended Trading$23.30 -0.08 (-0.34%) As of 05:48 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.TriSalus Life Sciences NASDAQ:TLSI$3.19 -0.03 (-0.93%) Closing price 05/27/2026 04:00 PM EasternExtended Trading$3.13 -0.06 (-1.85%) As of 04:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Abercrombie Rallies as Strong Q1 Earnings Extend Winning Streak Amazon's Alexa for Shopping Strengthens an Already Strong Bull Case TeraWulf Bets on Power Infrastructure to Lead AI Build-Out Zscaler Stock Drops 30%: Why the Dip Is a Buy Opportunity Shake Shack Insiders Buy as SHAK Stock Faces More Pressure Rocket Lab Keeps Making Headlines and Highs—Here's What's Driving the Latest Move Record Revenue, Rising Dividends—So Why Aren't Analysts Saying Buy? Qualcomm's TikTok AI Chip Deal Rewrites the Rules Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
